Antibody peptide based antifungal immunotherapy

Frontiers in Microbiology

Volumn 3, Issue JUN, 2012, Pages

  Magliani, Walter ^a   Conti, Stefania ^a   Giovati, Laura ^a   Zanello, Pier Paolo ^a   Sperindè, Martina ^a   Ciociola, Tecla ^a   Polonelli, Luciano ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Antibiobodies; Antifungal antibodies; Antifungal peptides; Killer peptides; Killer toxin; Synthetic cdrs

Indexed keywords

EID: 84875796159     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2012.00190     Document Type: Review

References (77)

1. Beninati, C., Oggioni, M. R., Boc-canera, M., Spinosa, M. R., Maggi, T., Conti, S., Magliani, W., De Bernardis, E, Teti, G., Cassone, A., Pozzi, G., and Polonelli, L. (2000). Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat. Biotechnol. 18, 1060-1064.
2. Binder, U., and Lass-Flörl, C. (2011). Epidemiology of invasive fungal infections in the Mediterranean area. Mediterr. J. Hematol. Infect. Dis. 3,e20110016.
3. Brena, S., Cabezas-Olcoz, J., Moragues, M. D., Fernández de Larrinoa, I.,Domínguez, A., Quindós, G., and Pontón, J. (2011). Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans. Antimicrob. Agents Chemother. 55, 3156-3163.
4. Bromuro, C., Romano, M., Chiani, P., Berti, F., Tontini, M., Proi-etti, D., Mori, E., Torosantucci, A., Costantino, P., Rappuoli, R., and Cassone, A. (2010). Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 28, 2615-2623.
5. Bromuro, C., Torosantucci, A., Chiani, P., Conti, S., Polonelli, L., and Cassone, A. (2002). Interplay betweenprotective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70, 5462-5470.
6. Brouwer, C. P., Rahman, M., and Welling, M. M. (2011). Discovery and development of a synthetic peptide derived from lactoferrin for clinical use. Peptides 32, 1953-1963.
7. Bryan, R. A., Guimaraes, A. J., Hopcraft, S., Jiang, Z., Bonilla, K., Mor-genstern, A., Bruchertseifer, F., Del Poeta, M., Torosantucci, A., Cassone, A., Nosanchuk, J. D.,Casadevall, A., and Dadachova, E. (2012). Toward developing a universal treatment for fungal disease using radioimmunother-apy targeting common fungal antigens. Mycopathologia. 173, 463-471.
8. Capodicasa, C., Chiani, P., Bromuro, C., De Bernardis, F., Catellani, M., Palma, A. S., Liu, Y., Feizi, T., Cassone, A., Benvenuto, E., and Torosantucci, A. (2011). Plant production of anti-β-glucan antibodies for immunother-apy of fungal infections in humans. Plant Biotechnol. J. 9, 776-787
9. Casadevall, A., Cassone, A., Bistoni, E, Cutler, J. E., Magliani, W., Murphy, J. W., Polonelli, L., and Romani,L. (1998). Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: an ongoing dilemma or an unnecessary dispute? Med. Mycol. 36(SUPPL. 1), 95-105.
10. Casadevall, A., and Pirofski, L. A. (2007). Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immuno-logical dogma. Infect. Immun. 75, 5074-5078.
11. Casadevall,A.,andPirofski,L.A. (2011). A new synthesis for antibody-mediated immunity. Nat. Immunol. 13,21-28.
12. Cassone, A., and Rappuoli, R. (2010). Universal vaccines: shifting to one for many. MBio 1, e00042-e00110.
13. Catiau, L., Traisnel, J., Chihib, N. E., Le Flem, G., Blanpain, A., Melnyk, O., Guillochon, D., and Nedjar-Arroume, N. (2011). RYH: a minimal peptidic sequence obtained from beta-chain hemoglobin exhibiting an antimicrobial activity. Peptides 32, 1463-1468.
14. Cenci, E., Bistoni, F., Mencacci, A., Perito, S., Magliani, W., Conti, S., Polonelli, L., and Vecchiarelli, A. (2004). A synthetic peptide as a novel anticryptococcal agent. Cell. Microbiol. 6,953-961.
15. Cenci, E., Mencacci, A., Spreca, A., Montagnoli, C., Bacci, A., Perruc-cio, K., Velardi, A., Magliani, W., Conti, S., Polonelli, L., and Romani, L. (2002). Protection of killer anti-idiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrowtransplantation. Infect. Immun. 70,2375-2382.
16. Cenci, E., Pericolini, E., Mencacci, A., Conti, S., Magliani, W., Bistoni, F., Polonelli, L., and Vecchiarelli, A. (2006). Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. J. Leukoc. Biol. 79, 40-45.
17. Chiani, P., Bromuro, C., Cassone, A., and Torosantucci, A. (2009). Anti-beta-glucan antibodies in healthy human subjects. Vaccine 27, 513-519.
18. Conti, S., Magliani, W., Giovati, L., Libri, I., Maffei, D. L., Salati, A., and Polonelli, L. (2008). Screening of a Saccharomyces cerevisiae nonessential gene deletion collection for altered susceptibility to a killer peptide. New Microbiol. 31,143-145.
19. D'Alessio, G. (2011). Denatured bactericidal proteins: active per se, or reservoirs of active peptides? FEBS Lett. 585, 2403-2404.Denning, D. W. (2003). Echinocan-din antifungal drugs. Lancet 362, 1142-1151.
20. Donini, M., Lico, C., Baschieri, S., Conti, S., Magliani, W., Polonelli, L., and Benvenuto, E. (2005). Production of an engineered killer peptide in Nico-tiana benthamiana by using a potato virus X expression system. Appl. Environ. Microbiol. 71, 6360-6367.
21. Foloppe,N. (2011).Thebenefits of constructing leads from fragment hits. FutureMed. Chem. 3, 1111-1115.
22. Gabrielli, E., Pericolini, E., Cenci, E., Ortelli, F., Magliani, W., Ciociola, T., Bistoni, F., Conti, S., Vecchiarelli, A., and Polonelli, L. (2009). Antibody complementarity-determining regions (CDRs): a bridge between adaptive and innate immunity. PLoS ONE 4, e8187. doi:10.1371/jour-nal.pone.0008187
23. Galay, R. L., Maeda, H., Aung, K. M., Umemiya-Shirafuji, R., Xuan, X., Igarashi, I., Tsuji, N., Tanaka, T., and Fujisaki, K. (2012). Anti-babesial activity of a potent peptide fragment derived from longicin of Haemaphysalis longicornis. Trop. Anim. Health Prod. 44, 343-348.
24. Gorr, S. U., Abdolhosseini, M., Shelar, A., and Sotsky, J. (2011). Dual host-defence functions of SPLUNC2/PSP and synthetic peptides derived from the protein. Biochem. Soc. Trans. 39, 1028-1032.
25. Guyard, C., Dehecq, E., Tissier, J. P., Polonelli, L., Dei-Cas, E., Cailliez, J. C., and Menozzi, E D. (2002). Involvement of [beta] -glucans in the wide-spectrum antimicrobial activity of Williopsis saturnus var. mrakii MUCL 41968 killer toxin. Mol. Med. 8, 686-694.
26. Ibrahim, H. R., Imazato, K., and Ono, H. (2011). Human lysozyme possesses novel antimicrobial peptides within its N-terminal domain that target bacterial respiration. J. Agric. Food Chem. 59, 10336-10345.
27. Iorio, E., Torosantucci, A., Bromuro, C., Chiani, P., Ferretti, A., Gian-nini, M., Cassone, A., and Podo, F. (2008). Candida albicans cell wall comprises a branched beta-D-(1→6)-glucan with beta-D-(1→3)-side chains. Carbohydr. Res. 343, 1050-1061.
28. Kabir, M. E., Karim, N., Krishnaswamy, S., Selvakumar, D., Miyamoto, M., Furuichi, Y., and Komiyama, T. (2011). Peptide derived from anti-idiotypic single-chain antibody is a potent antifungal agent compared to its parent fungicide HM-1 killer toxin peptide. Appl Microbiol. Biotechnol. 92, 1151-1160
29. Kasetty, G., Papareddy, P., Kalle, M., Rydengård,V.,Mörgelin,M.,Albiger, B., Malmsten, M., and Schmidtchen, A. (2011). Structure-activity studies and therapeutic potential of host defense peptides of human throm-bin. Antimicrob. Agents Chemother. 55,2880-2890.
30. Kauffman, C. A. (2006). Fungal infections. Proc. Am. Thorac. Soc. 3, 35-40.
31. Magliani, W., Conti, S., Cassone, A., De Bernardis, F., and Polonelli, L. (2002). New immunotherapeutic strategies to control vaginal candidi-asis. Trends Mol Med. 8, 121-126.
32. Magliani, W., Conti, S., Cunha, R. L., Travassos, L. R., and Polonelli, L. (2009). Antibodies as crypts of antiinfective and antitumor peptides. Curr. Med. Chem. 16, 2305-2323.
33. Magliani, W., Conti, S., De Bernardis, E, Gerloni, M., Bertolotti, D., Moz-zoni, P., Cassone, A., and Polonelli, L. (1997a). Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat. Biotechnol. 15, 155-158.
34. Magliani, W., Conti, S., Gerloni, M., Bertolotti, D., and Polonelli, L. (1997b). Yeast killer systems. Clin. Microbiol Rev. 10, 369-400.
35. Magliani, W., Conti, S., Frazzi, R., Ravanetti, L., Maffei, D. L., and Polonelli, L. (2005). Protective antifungal yeast killer toxin-like antibodies. Curr. Mol Med. 5, 443-452.
36. Magliani, W., Conti, S., Giovati, L., Maffei, D. L., and Polonelli, L. (2008a).Anti-beta-glucan-like immunoprotective candidacidal antiidiotypic antibodies. Front. Biosci. 13,6920-6937.
37. Magliani, W., Conti, S., Travassos, L. R., and Polonelli, L. (2008b). From yeast killer toxins to antibiobodies and beyond. FEMS Microbiol Lett. 288, 1-8.
38. Magliani, W., Conti, S., Salati, A., Arseni, S., Ravanetti, L., Frazzi, R., and Polonelli, L. (2004a). Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr. Med. Chem. 11, 1793-1800.
39. Magliani, W., Conti, S., Salati, A., Vac-cari, S., Maffei, D. L., and Polonelli, L. (2004b). Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Res. 5, 11-18.
40. Manfredi, M., McCullough, M. J., Conti, S., Polonelli, L., Vescovi, P., Al-Karaawi, Z. M., and Porter, S. R. (2005). In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptideagainst oral isolates of Candida spp. differently susceptible to conventional antifungals. Oral Microbiol. Immunol 20,226-232.
41. Manfredi, M., Merigo, E., Salati, A., Conti, S., Savi, A., Polonelli, L., Bonanini, M., and Vescovi, P. (2007). In vitro candidacidal activity of a synthetic killer decapeptide (KP) against Candida albicans cells adhered to resin acrylic discs. J. Oral Pathol Med. 36, 468-471.
42. Matthews, R. C., Rigg, G., Hodgetts, S., Carter, T., Chapman, C., Gregory, C., Illidge, C., and Burnie, J. (2003). Preclinical assessment of the efficacy of mycograb, a human recombi-nant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47, 2208-2216.
43. Moragues, M. D., Omaetxebarria, M. J., Elguezabal, N., Sevilla, M. J., Conti, S., Polonelli, L., and Ponton, J. (2003). A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect. Immun. 71, 5273-5279.
44. Ng, J. H., and Ilag, L. L. (2006). Cryptic protein fragments as an emerging source of peptide drugs. IDrugs 9, 343-346.
45. Park, Y., and Hahm, K. S. (2012). Novel short AMP: design and activity study. Protein Pept. Lett. 19, 652-656.
46. Pasikowski, P., Gozdziewicz, T., Ste-fanowicz, P., Artym, J., Zimecki, M., and Szewczuk, Z. (2011). A novel immunosuppressory peptide originating from the ubiquitin sequence. Peptides 32, 2418-2427.
47. Pertinhez, T. A., Conti, S., Ferrari, E., Magliani, W., Spisni, A., and Polonelli, L. (2009). Reversible self-assembly: a key feature for a new class of autodelivering therapeutic peptides. Mol Pharm. 6,1036-1039.
48. Pettoello-Mantovani, M., Nocerino, A., Polonelli, L., Morace, G., Conti, S., Di Martino, L., De Ritis, G., Iafusco, M., and Guandalini, S. (1995). Hansenula anomala killer toxin induces secretion and severe acute injury in the rat intestine. Gastroenterology 109, 1900-1906.
49. Pimenta, D. C., and Lebrun, I. (2007). Cryptides: buried secrets in proteins. Peptides 28, 2403-2410.
50. Polonelli, L., Casadevall, A., Han, Y., Bernardis, F., Kirkland, T. N., Matthews, R. C., Ariani, D., Boc-canera, M., Burnie, J. P., Cassone, A., Conti, S., Cutler, J. E., Frazzi, R., Gregory, C., Hodgetts, S., Illidge, C., Magliani, W., Rigg, G., and Santoni, G. (2000). The efficacy of acquired humoral and cellular immunityin the prevention and therapy of experimental fungal infections. Med. Mycol. 38(Suppl. 1), 281-292.
51. Polonelli, L., Ciociola, T., Magliani, W., Zanello, P. P., D'Adda, T., Galati, S., De Bernardis, F., Arancia, S., Gabrielli, E., Pericolini, E., Vec-chiarelli, A., Arruda, D. C., Pinto, M. R., Travassos, L. R., Pertin-hez, T. A., Spisni, A., and Conti, S. (2012). Peptides of the constant region of antibodies display fungi-cidal activity. PLoS ONE 7, e34105. doi:10.1371/journal.pone.0034105
52. Polonelli, L., Conti, S., Gerloni, M., Magliani, W., Castagnola, M., Morace, G., and Chezzi, C. (1991). "Antibiobodies": antibiotic-like anti-idiotypic antibodies. J. Med. Vet. Mycol. 29,235-242.
53. Polonelli, L., De Bernardis, F., Conti, S., Boccanera, M., Gerloni, M., Morace, G., Magliani, W., Chezzi, C., and Cassone, A. (1994). Idiotypic intrav-aginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies.J. Immunol. 152,3175-3182.
54. Polonelli, L., De Bernardis, F., Conti, S., Boccanera, M., Magliani, W., Gerloni, M., and Cassone, A. (1996). Human natural yeast killer toxin-like candidacidal antibodies. J. Immunol. 156, 1880-1885.
55. Polonelli, L., Fanti, F., Conti, S., Cam-pani, L., Gerloni, M., Castagnola, M., Morace, G., and Chezzi, C. (1990). Detection by immunofluo-rescent anti-idiotypic antibodies of yeast killer toxin cell wall receptors of Candida albicans. J. Immunol. Methods 132,205-209.
56. Polonelli, L., Lorenzini, R., De Bernardis, F., Gerloni, M., Conti, S., Morace, G., Magliani, W., and Chezzi, C. (1993). Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scand. J. Immunol. 37, 105-110.
57. Polonelli, L., Lorenzini, R., De Bernardis, F., and Morace, G. (1986). Potential therapeutic effectof yeast killer toxin. Mycopathologia 96, 103-107.
58. Polonelli, L., Magliani, W., Conti, S., Bracci, L., Lozzi, L., Neri, P., Adriani, D., De Bernardis, F., and Cassone, A. (2003). Therapeutic activity of an engineered synthetic killer anti-idiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun. 71, 6205-6212.
59. Polonelli, L., and Morace, G. (1986). Reevaluation of the yeast killer phenomenon. J. Clin. Microbiol. 24, 866-869.
60. Polonelli, L., and Morace, G. (1987). Production and characterization of yeast killer toxin monoclonal antibodies. J. Clin. Microbiol. 25, 460-462.
61. Polonelli, L., and Morace, G. (1988). Yeast killer toxin-like anti-idiotypic antibodies. J. Clin. Microbiol. 26, 602-604.
62. Polonelli, L., Pontón, J., Elguezabal, N., Moragues, M. D., Casoli, C., Pilotti, E., Ronzi, P., Dobroff, A. S., Rodrigues,E. G., Juliano,M.A., Maf-fei, D. L., Magliani, W., Conti, S., and Travassos, L. R. (2008). Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and anti-tumor activities. PLoS ONE 3,e2371. doi:10.1371/journal.pone.0002371
63. Polonelli, L, Seguy, N., Conti, S., Gerloni, M., Bertolotti, D., Can-telli, C., Magliani, W., and Cail-liez, J. C. (1997). Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies. Clin. Diagn. Lab. Immunol. 4, 142-146.
64. Rachini, A., Pietrella, D., Lupo, P., Torosantucci, A., Chiani, P., Bro-muro, C., Proietti, C., Bistoni, F., Cassone, A., and Vecchiarelli, A. (2007). An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryp-tococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75, 5085-5094
65. Samir, P., and Link, A. J. (2011). Analyzing the cryptome: uncovering secret sequences. AAPS J. 13, 152-158.
66. Séguy, N., Cailliez, J. C., Delcourt, P., Conti, S., Camus, D., Dei-Cas, E., and Polonelli, L. (1997). Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii. Mol. Med. 3, 544-552.
67. Séguy, N., Polonelli, L., Dei-Cas, E., and Cailliez, J. C. (1998). Effect of a killer toxin of Pichia anom-ala to Pneumocystis. Perspectives in the control of pneumocystosis. FEMS Immunol. Med. Microbiol. 22, 145-149.
68. Selvakumar, D., Miyamoto, M., Furuichi, Y., and Komiyama, T. (2006). Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies. Antimicrob. Agents Chemother. 50, 3090-3097.
69. Sobel, J. D. (1997). Vaginitis. N. Engl. J. Med. 337, 1896-1903.
70. Sonesson, A., Kasetty, G., Olin, A. I., Malmsten, M., Mörgelin, M., Sørensen, O. E., and Schmidtchen, A. (2011a). Thymic stromal lym-phopoietin exerts antimicrobial activities. Exp. Dermatol. 20, 1004-1010.
71. Sonesson, A., Nordahl, E. A., Malmsten, M., and Schmidtchen, A. (2011b). Antifungal activities of peptides derived from domain 5 of high-molecular-weight kininogen. Int. J. Pept. 2011,761037.
72. Torosantucci, A., Bromuro, C., Chiani, P., De Bernardis, F., Berti, F., Galli, C., Norelli, F., Bellucci, C., Polonelli, L., Costantino, P., Rappuoli, R., and Cassone, A. (2005). A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597-606.
73. Travassos, L. R., Silva, L. S., Rodrigues, E. G., Conti, S., Salati, A., Magliani, W., and Polonelli, L. (2004). Therapeutic activity of a killer peptide againstexperimental paracoccidioidomyco-sis. J. Antimicrob. Chemother. 54, 956-958.
74. Ueki, N., Someya, K., Matsuo, Y., Waka-matsu, K., and Mukai, H. (2007). Cryptides: functional cryptic peptides hidden in protein structures. Biopolymers 88, 190-198.
75. Vinh, D. C. (2011). Insights into human antifungal immunity from primary immunodeficiencies. Lancet Infect. Dis. 11,780-792.
76. Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., and Edmond, M. B. (2004). Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317.
77. Zhai, B., and Lin, X. (2011). Recent progress on antifungal drug development. Curr. Pharm. Biotechnol. 12, 1255-1262.